7M6H
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG7-20
7M6H の概要
エントリーDOI | 10.2210/pdb7m6h/pdb |
EMDBエントリー | 23696 |
分子名称 | Spike glycoprotein, BG7-20 Fab Heavy Chain, BG7-20 Fab Light Chain, ... (4 entities in total) |
機能のキーワード | sars-cov-2, coronavirus, covid-19, antibody, neutralizing antibody, receptor binding domain, spike glycoprotein, antiviral protein, viral protein-antiviral protein complex, viral protein/antiviral protein |
由来する生物種 | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2, COVID-19 virus) 詳細 |
タンパク質・核酸の鎖数 | 7 |
化学式量合計 | 520811.70 |
構造登録者 | |
主引用文献 | Scheid, J.F.,Barnes, C.O.,Eraslan, B.,Hudak, A.,Keeffe, J.R.,Cosimi, L.A.,Brown, E.M.,Muecksch, F.,Weisblum, Y.,Zhang, S.,Delorey, T.,Woolley, A.E.,Ghantous, F.,Park, S.M.,Phillips, D.,Tusi, B.,Huey-Tubman, K.E.,Cohen, A.A.,Gnanapragasam, P.N.P.,Rzasa, K.,Hatziioanno, T.,Durney, M.A.,Gu, X.,Tada, T.,Landau, N.R.,West Jr., A.P.,Rozenblatt-Rosen, O.,Seaman, M.S.,Baden, L.R.,Graham, D.B.,Deguine, J.,Bieniasz, P.D.,Regev, A.,Hung, D.,Bjorkman, P.J.,Xavier, R.J. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell, 184:3205-, 2021 Cited by PubMed Abstract: Monoclonal antibodies (mAbs) are a focus in vaccine and therapeutic design to counteract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. Here, we combined B cell sorting with single-cell VDJ and RNA sequencing (RNA-seq) and mAb structures to characterize B cell responses against SARS-CoV-2. We show that the SARS-CoV-2-specific B cell repertoire consists of transcriptionally distinct B cell populations with cells producing potently neutralizing antibodies (nAbs) localized in two clusters that resemble memory and activated B cells. Cryo-electron microscopy structures of selected nAbs from these two clusters complexed with SARS-CoV-2 spike trimers show recognition of various receptor-binding domain (RBD) epitopes. One of these mAbs, BG10-19, locks the spike trimer in a closed conformation to potently neutralize SARS-CoV-2, the recently arising mutants B.1.1.7 and B.1.351, and SARS-CoV and cross-reacts with heterologous RBDs. Together, our results characterize transcriptional differences among SARS-CoV-2-specific B cells and uncover cross-neutralizing Ab targets that will inform immunogen and therapeutic design against coronaviruses. PubMed: 34015271DOI: 10.1016/j.cell.2021.04.032 主引用文献が同じPDBエントリー |
実験手法 | ELECTRON MICROSCOPY (4 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード